Name: Spartan Overseas Shipping Corp.
Address: 181 South Franklin Ave., Valley Stream, NY 11581
Date Revoked: November 1, 1995
Reason: Surrendered license voluntarily.

License Number: 3382
Name: W.I.D.E. Corporation
Address: 850 Center Drive, Elizabeth, NJ 07201
Date Revoked: November 5, 1995
Reason: Failed to maintain a valid surety bond.

License Number: 2097
Name: Concept Cargo, Inc.
Address: 8269–8287 N.W. 54th Street, Miami, FL 33166
Date Revoked: November 20, 1995
Reason: Surrendered license voluntarily.

License Number: 2825
Name: Henry L. Rosich dba Rosich Forwarding Company
Address: 409 Warren Boulevard, Broomall, PA 19008
Date Revoked: November 20, 1995
Reason: Surrendered license voluntarily.

Bryant L. VanBrakle,

Director, Bureau of Tariffs, Certification and Licensing.

[FR Doc. 95–29928 Filed 12–7–95; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Scotland Bancorp, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than January 2, 1996.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. Scotland Bancorp, Inc., Laurinburg, North Carolina; to become a bank holding company by acquiring 100 percent of the voting shares of Scotland Savings Bank, SSB, Laurinburg, North Carolina.

B. Federal Reserve Bank of Atlanta (Zane R. Kelley, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303:

1. Republic Bancshares, Inc., St. Petersburg, Florida; to become a bank holding company by acquiring 100 percent of the voting shares of Republic Bank, St. Petersburg, Florida. Comments regarding this notice should be received not later than December 22, 1995.

Board of Governors of the Federal Reserve System, December 4, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–29931 Filed 12–07–95; 8:45 am]

BILLING CODE 6210–01–F

Southern National Corporation, et al.; Notice of Applications to Engage de novo in Permissible Nonbanking Activities

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 22, 1995.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. Southern National Corporation, Winston-Salem, North Carolina; to engage *de novo* in making, acquiring, or servicing loans or other extensions of credit pursuant to § 225.25(b)(1) of the Board's Regulation Y.

B. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. South Plains Financial, Inc., Lubbock, Texas; to engage *de novo* through its subsidiary, South Plains Financial Services, Inc., Lubbock, Texas, in providing for others, data processing and data transmission services, facilities (including data processing and data transmission hardware, software, documentation or operating personnel), pursuant to § 225.25(b)(7) of the Board's Regulation Y, and in performing real estate and personal property appraisals, including tangible and intangible personal property, pursuant to § 225.25(b)(13) of the Board's Regulation Y. These activities will take place in the state of Texas.

Board of Governors of the Federal Reserve System, December 4, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95–29932 Filed 12–8–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration (SAMHSA) Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of

the Substance Abuse and Mental Health Services Administration (SAMHSA) National Advisory Council in January 1996.

The meeting of the SAMHSA National Advisory Council will include discussions concerning SAMHSA's Reauthorization; update on SAMHSA's demonstration program; SAMHSA's Managed Care Initiative, including the role of SAMHSA in developing mental health and substance abuse standards for managed care facilities; report on the Performance Partnership Development Process and Regional Meetings; and a report on the Co-Occurring Meeting. In addition various constituency organizations will be describing their collaborative efforts around the development of performance measures and outcomes monitoring, and exemplary community based programs will be describing their efforts to prevent and treat mental and addictive disorders. Finally, there will be status reports by the Council's work groups on Health Care Reform and Children's Services. Attendance by the public will be limited to space available.

The meeting will also include the review, discussion and evaluation of contract proposals. Therefore a portion of the meeting will be closed to the public as determined by the Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c) (3), (4) and (6) and 5 U.S.C. app. 2 10(d).

A summary of the meeting and a roster of Council members may be obtained from: Ms. Susan E. Day, Program Assistant, SAMHSA National Advisory Council, 5600 Fishers Lane, Room 12C–15, Rockville, Maryland 20857. Telephone: (301) 443–4640.

Substantive program information may be obtained from the contact whose name and telephone number is listed below.

Committee Name: Substance Abuse and Mental Health Services Administration, National Advisory Council.

Meeting Date: January 22, 1996.

Place: Omni-Shoreham Hotel, 2500 Calvert Street, N.W., Washington, DC 20008.

Open: January 22, 1996, 9:00 a.m. to 4:30 p.m.

Closed: January 22, 1996, 5:00 p.m. to 6:00 p.m.

Contact: Toian Vaughn, Room 12C–15, Parklawn Building, telephone (301) 443–4640 and FAX (301) 443–1450.

Dated: December 4, 1995.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 95–29934 Filed 12–7–95; 8:45 am]

BILLING CODE 4162–20–P

Food and Drug Administration

[Docket No. 95N–0371]

Interim Definition and Elimination of Lot-by-Lot Release For Well-Characterized Therapeutic Recombinant DNA-Derived and Monoclonal Antibody Biotechnology Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an interim definition for well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. FDA is also announcing that FDA is eliminating lot-by-lot release for licensed well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. After approval, manufacturers of such products are no longer requested to submit samples and protocols for individual lots of products to the Center for Biologics Evaluation and Research (CBER) for routine lot-by-lot release. Manufacturers may begin distributing products affected by this policy after notification by CBER and without awaiting approval of a supplement to their product license applications. This notice is intended to reduce unnecessary burdens for industry without diminishing public health protection.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857. Comments should be identified with the docket number found in brackets in the heading of this document. Two copies of any comments are to be submitted, except that individuals may submit one copy. Received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT:

Regarding lot release: Jerome A. Donlon, Center for Biologics Evaluation and Research (HFM–200), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2200.

Regarding the definition of a well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology product: Jean M. Olson, Center for Biologics Evaluation and Research (HFM–630), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–3074.

SUPPLEMENTARY INFORMATION: This notice is being issued in accordance with the principles set forth in Executive Order 12866. Executive Order 12866 directs Federal agencies to implement measures that will reform and streamline the regulatory process to avoid unnecessary regulatory burdens. In the November 1995 ''Reinventing the Regulation of Drugs Made from Biotechnology'' report, the President and Vice President announced a series of regulatory reform initiatives, including FDA's intention to issue a notice eliminating lot-by-lot release for licensed well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. FDA made a commitment to issue the notice within 30 days of the report.

Elimination of Lot-by-Lot Release

Biologics have traditionally been complex mixtures of substances produced primarily from living organisms, and have been difficult to characterize by precise tests. They include vaccines, products made from human or animal blood, and other products made from a variety of materials. Because of the inherent variability of these products, each individual lot of most biological products has been subject to evaluation and testing by CBER prior to release.

Under § 610.2 (21 CFR 610.2), the Director of CBER may require, at any time, that samples of a licensed product, protocols, and test results be submitted to CBER for official release. FDA has invoked lot-by-lot release to help ensure that products continue to meet established standards before they are distributed.

Historically, lot-by-lot release has served an important role in the regulation of biotechnology products and has prevented the distribution of unacceptable lots. However, greater control has been achieved by manufacturers over the production of biotechnology products through in-process controls, process validation, and advances in analytical techniques. For well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products, as defined below, FDA has found that once a company has demonstrated its ability to consistently produce acceptable lots, and has procedures in place that will prevent the release of lots that do not meet release specifications, it is not necessary for FDA to verify that each